Global Markets Direct’s, 'Ovarian Disease - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Disease. Ovarian Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Ovarian Disease. - A review of the Ovarian Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ovarian Disease pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Ovarian Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Ovarian Disease pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Ovarian Disease - Pipeline Review, H1 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ovarian Disease Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Ovarian Disease 7 Ovarian Disease Therapeutics under Development by Companies 9 Ovarian Disease Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 11 Comparative Analysis 11 Discovery and Pre-Clinical Stage Products 12 Comparative Analysis 12 Ovarian Disease Therapeutics - Products under Development by Companies 13 Ovarian Disease Therapeutics - Products under Investigation by Universities/Institutes 14 Companies Involved in Ovarian Disease Therapeutics Development 15 IBSA Institut Biochimique SA 15 Respiratorius AB 16 Ovarian Disease - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 22 SPOC - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 Merional - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 PTEN Inhibitor - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 degarelix - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 Recombinant Humam Serum Albumin Biosimilar - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 Gonadotropin-Releasing Hormone Antagonists - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 Ovarian Disease Therapeutics - Dormant Products 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables
Number of Products Under Development for Ovarian Disease, H1 2013 7 Products under Development for Ovarian Disease - Comparative Analysis, H1 2013 8 Number of Products under Development by Companies, H1 2013 9 Number of Products under Investigation by Universities/Institutes, H1 2013 10 Comparative Analysis by Late Stage Development, H1 2013 11 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12 Products under Development by Companies, H1 2013 13 Products under Investigation by Universities/Institutes, H1 2013 14 IBSA Institut Biochimique SA, H1 2013 15 Respiratorius AB, H1 2013 16 Assessment by Monotherapy Products, H1 2013 17 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Stage and Molecule Type, H1 2013 21 Ovarian Disease Therapeutics - Dormant Products 28
List of Figures
Number of Products under Development for Ovarian Disease, H1 2013 7 Products under Development for Ovarian Disease - Comparative Analysis, H1 2013 8 Products under Development by Companies, H1 2013 9 Products under Investigation by Universities/Institutes, H1 2013 10 Late Stage Products, H1 2013 11 Discovery and Pre-Clinical Stage Products, H1 2013 12 Assessment by Monotherapy Products, H1 2013 17 Assessment by Route of Administration, H1 2013 18 Assessment by Stage and Route of Administration, H1 2013 19 Assessment by Molecule Type, H1 2013 20 Assessment by Stage and Molecule Type, H1 2013 21